Abstract: The present invention forms a detection layer in an embedded biosensor probe by using a phenazine derivative as a redox mediator in which a phenazine group is covalently bonded to a high molecular weight polymer having a carboxyl group or an amino group, such as polyamino acid, polyimine, or polyallylamine; and the distance between the phenazine group and the high molecular weight polymer main chain is increased by using a polyethylene glycol chain.

Abstract: A method for maintaining the health of a diabetic patient by preventing onset of diabetic ketoacidosis in said patient, the method comprising: prescribing an SGLT2 inhibitor for administration to a patient in need thereof; providing at least one test strip for identifying the presence of ?-hydroxybutyrate in the patient's urine; and upon indication of the presence of ?-hydroxybutyrate in the patient's urine, discontinuing the administration of the SGLT2 inhibitor. Also disclosed is a kit useful in the monitoring of risk of onset of diabetic ketoacidosis in patients taking an SGLT2 inhibitor, the kit comprising: the SGLT2 inhibitor and at least one test strip to identify the presence of ?-hydroxybutyrate in the patient's urine, wherein the at least one test strip undergoes a change in color upon detection of ?-hydroxybutyrate in the patient's urine.

Abstract: A blood glucose level measuring chip exhibits excellent blood spreading ability and can maintain a reaction rate of blood with a reagent, even where the blood has a high hematocrit value (Ht). The blood glucose level measuring chip includes a blood glucose level measuring reagent including a supply port through which blood is supplied, a flow path having the supply port formed at one end of the flow path, and a blood glucose level measuring reagent containing an aromatic hydrocarbon having at least one sulfonic acid group disposed on an inner wall defining the flow path, wherein a ratio A/B is 3.7 mmol/L or more to 184.8 mmol/L when A (mmol) represents the total molar amount of aromatic hydrocarbons contained in the blood glucose level measuring reagent, and B (L) represents a volume of a region in which the blood glucose level measuring reagent and the blood are dissolved.

Abstract: The present invention belongs to the technical field of immunotherapy. A method of using dimethylarginine derivatives to inhibit the proliferation of lymphocyte. ADMA, SDMA, and their derivative DMGV can inhibit T cells and/or B cells proliferation in vitro by inducing mitochondrial ROS. ADMA and SDMA can induce mitochondrial ROS generation by the action of alanine-glyoxylate aminotransferase 2 (AGXT2), which converts both ADMA and SDMA into dimethylguanidino valeric acid (DMGV) in the mitochondria. The dimethylarginine dimethylamino hydrolase (DDAH) inhibitor PD404182 also inhibits T cell proliferation by allowing more ADMA and SDMA to be converted to DMGV. As a clinical relevance, DMGV effectively treated arthritis in mice which was caused by activated T cells.

Abstract: Devices, systems, and methods are used for personalized monitoring of changes in metabolism as a function of external parameters such as food or physical exercise. More particularly, the present disclosure relates to electrochemical strips for detecting the amount of biomarker for fat metabolism, in particular, glycerol.

Abstract: In a method for producing acetoin, butanediol, or butanol from ethanol according to the present invention, a cell-free catalysis method was used by designing an artificial synthetic pathway so that proteins of NOX, EtDH, FLS, BDH, and DDH and variant proteins thereof exhibit cascade catalytic activity as enzymes. Compared to existing fermentation methods using microorganisms, the production method according to the present invention does not require cell growth and has a short synthetic pathway, a fast reaction rate, high yield and productivity, adjustment of targeted reaction conditions is convenient, and butanol may be effectively produced. Moreover, same may be reused numerous times by fixing the proteins to nano-particles, and are also effective for producing acetoin, butanediol, or butanol, thus being economical. Therefore, the production method may be usefully adopted in the relevant industries requiring acetoin, butanediol, or butanol.

Abstract: The present invention relates to a method for stabilizing an enzyme by storing the enzyme in the presence of a stable coenzyme. The present invention further relates to an enzyme stabilized with a stable coenzyme, and to the use thereof in test elements for detecting analytes.

Abstract: A composition for inducing dedifferentiation from cancer cells to cancer stem cells comprising a ribosome-activating inhibitor as an active ingredient, a method of culturing a cancer organoid based thereon and an anticancer drug screening platform, and the increase of colorectal cancer stem cell group induced by the exposure of ribosome-inactivating stress was regulated by the ATF3 gene.

Abstract: The present invention provides methods, kits, and compositions for purifying HDL molecules from a sample (e.g., blood sample) using HDL tagging molecules comprising an HDL lipophilic core binding peptide (e.g., portion of ApoA1) and an affinity tag. The present invention also provides methods, kits, and compositions for detecting non-fragmented ApoA1 with mass spectrometry. The present invention further provides methods, kits, and compositions for tagging HDL molecules in a sample with detectably labeled ApoA1 molecules such that the ratio of detectably labeled ApoA1 molecules to native ApoA1 proteins may be determined.

Abstract: An aqueous composition includes (i) glutamate dehydrogenase from a bacterium of the Clostridium genus, (ii) a stabilizing compound that is a carboxylic acid having a carbon-based chain of at least three carbon atoms and comprising at least two —COOH groups, or a salt thereof, and (iii) any of a monosaccharide polyol, disaccharide polyol, or polymeric macromolecule in addition to the glutamate dehydrogenase. A process for stabilizing the glutamate dehydrogenase in order to maintain antigenic properties of the glutamate dehydrogenase includes stabilizing the glutamate dehydrogenase in the aqueous composition and maintaining the antigenic properties of the glutamate dehydrogenase during storage of the aqueous composition.

Abstract: Provided is a method for increasing the proportion of memory T cells in a T cell population, said method comprising a step of adding a modulator for the retinoid metabolic pathway and/or a modulator for the retinoic acid signaling system to the T cell population.

Abstract: An apparatus and method for replenishing urease in a sorbent cartridge for use in sorbent dialysis using urease pouches. The sorbent cartridge is configured to allow insertion of a urease pouch or injection of a urease solution into the sorbent cartridge containing a urease pouch. The sorbent module can also comprise other, rechargeable, sorbent materials for removing toxins other than urea from spent dialysate.

Abstract: Methods of diagnosing subjects having a cell proliferation-related disorder or suspected of having a cell proliferation-related disorder associated with mutant IDH enzymes with 2HG neoactivity.

Abstract: A sensing sensor includes a main body portion, a piezoelectric resonator, a connecting terminal, and an information storage. The main body portion includes a supply region to which the sample solution is supplied. The piezoelectric resonator is disposed to face the supply region and includes a capturing layer that captures a sensing object. The connecting terminal is configured to attachably/detachably connect a conductive path connected to an electrode of the piezoelectric resonator to a frequency measuring unit. The information storage stores calibration curve information to specify a calibration curve that indicates a relationship between a density of the sensing object and a frequency variation amount of the piezoelectric resonator before and after supplying the sample solution.

Abstract: A process for stabilizing glutamate dehydrogenase (GDH) from a bacterium of the Clostridium genus, in an aqueous solution, in order to maintain the antigenic properties thereof, includes the step of mixing the glutamate dehydrogenase and a stabilizing composition which is a carboxylic acid having a carbon-based chain of at least 3 carbon atoms and comprising at least 2 —COOH groups, or a salt thereof. GDH compositions thus stabilized and a method of detecting the presence of bacteria of the Clostridium genus are also disclosed.

Abstract: An electrode that comprises a nanostructured material that comprises pyrolyzed date palm leaves that are obtained from a pyrolysis of an agro-waste containing date palm leaves in an inert gas and in a temperature range of 800 to 1600° C., an electrochemical cell thereof, and a method of determining a hydroquinone concentration in a hydroquinone-containing solution with the electrochemical cell. Various combinations of embodiments are also provided.

Abstract: Provided are an image extraction system, an image extraction method, and an image extraction program that extract an image matched with a theme. A first theme and a second theme are determined from a plurality of images. In a case in which the determined second theme is changed, the changed second theme is input. A first image extraction process that extracts an image from the plurality of images on the basis of the first theme is performed and a second image extraction process that extracts an image from the plurality of images on the basis of the second theme is performed. The extracted images are displayed.

Abstract: A biosensor for the detection of an analyte such as ascorbic acid is provided. Also provided is a device comprising the biosensor. In addition, methods of detecting analytes such as ascorbic acid in a sample, and methods of a point-of-care diagnosis of eye disease and eye injury are provided.

Abstract: Methods of treating and evaluating subjects having neoactive mutants of IDH (e.g., IDH1 or IDH2).

Abstract: Proteins that are electrophoretically separated in a gel are derivatized to produce fluorescent emissions by incorporating halo-substituted organic compounds into one or both of the electrode buffer solutions at the two ends of the gel. The halo-substituted compounds used are ones that bear an electric charge at the pH of the buffer solutions and gel, and the polarity of the charge on the compounds is such that the compounds migrate from the electrode buffer into the gel under the electrophoretic influence concurrently with the migration of the proteins into the gel. Once the proteins are separated and distributed within the gel and the gel is fully penetrated with the halo-substituted compounds, the gel is irradiated with ultraviolet light to induce a reaction between the halo-substituted compounds and the proteins through the tryptophan residues on the proteins, producing fluorescent reaction products.

Abstract: One example discloses a substance detection device, including: a substrate configured to carry a substance; wherein the substrate has a length and a substance loss along the length of the substrate; a test region coupled to the substrate and configured to bond to at least a portion of the substance; a sensor coupled to the substrate at a fixed location along the length and having a sensing signal output; an integration circuit coupled to the sensor and configured to integrate, over a time interval, a signal from the sensing signal output; and a detection circuit coupled to the integration circuit and configured to output a substance detected signal if the integrated sensing signal output signal deviates from the substance loss corresponding to the fixed sensor location.

Abstract: The present invention discloses functional nitrite reductase as a potential drug target for anti-tubercular drug development. The present invention also relates to the development of an easy method for identification of nitrite in clinical samples as well as its correlation with the severity of the disease. Presence of active as well as dormant/latent stages of Mycobacterium tuberculosis (MTB) could be identified from nitrite in clinical samples like sputum of potential TB patients.

Abstract: Compositions, devices, kits and methods are disclosed for assaying glucose with a glycosylated, modified flavin adenine dinucleotide-dependent glucose dehydrogenase (FAD-GDH), variant thereof or an active fragment thereof, where at least one asparagine residue at positions N2, N168 and N346 of mature, wild-type A. oryzae FAD-GDH according to SEQ ID NO:2 is substituted by one or more amino acids not suitable for glycosylation, thereby eliminating or inactivating, respectively, a potential glycosylation site at this position.

Abstract: A system for identifying a bio-marker using mass spectroscopy is provided that includes a sample receptacle configured to receive a tissue sample, a mass spectrometry apparatus configured to receive the tissue sample and analyze the tissue sample using a mass spectrometry process to generate mass spectrometry data, and a computer system that includes a computer processor having access to a non-transitory, computer-readable storage medium having stored thereon instructions. The instructions cause the computer processor to: receive the mass spectrometry data from the mass spectrometry apparatus; analyze the mass spectrometry data to determine a presence of 2-Hydroxyglutarate (2-HG) in the tissue sample; and generate a report indicating a health of the tissue sample based on the presence of 2-HG in the tissue sample.

Abstract: Methods and assays for detecting S-sulfhydration of amino acids in proteins, polypeptides and peptides are provided. The method is a two-step “tag-switch” method employing two reagents consecutively to specifically label, with a detectable label, persulfide (—S—SH) linkages in proteins, polypeptides and peptides.

Abstract: Disclosed is a daidzein derivative as represented by formula (I), or pharmaceutically acceptable salt thereof. Compared to the daidzein in the prior art, the daidzein derivative hydrochloride, in particular to the 7-O—N,N-diethyl-aminoacetyl daidzein hydrochloride, prepared by the daidzein derivative of the present invention, has better solubility and effect for treating cardiovascular diseases.

Abstract: The present disclosure relates to an electrochemical test sensor for detecting the concentration of an analyte in a fluid sample. The test sensor includes a working electrode, a counter electrode, and a trigger electrode. A temporary protective layer overlies the trigger electrode and helps to maintain the function of the trigger electrode during test sensor manufacture.

Abstract: The invention relates to 12 ?-hydroxysteroid dehydrogenases, nucleic acid sequences coding for the same, expression cassettes and vectors, recombinant microorganisms containing the corresponding coding nucleic acid sequences, a method for producing said 12 ?-hydroxysteroid dehydrogenases, a method for enzymatic oxidation of 12 ?-hydroxysteroids using said enzyme, a method for enzymatic reduction of 12-ketosteroids using said enzyme, a method for qualitative or quantitative determination of 12-ketosteroids and/or 12?-hydroxysteroids using said 12?-hydroxysteroid dehydrogenases and a method for production of ursodesoxycholic acid, comprising the enzyme-catalyzed cholic acid oxidation using said 12 ?-hydroxysteroid dehydrogenases.

Abstract: The present invention relates to a testing system for analyzing a risk of developing organ failure or presence of organ failure, said system comprising a disposable testing device arranged to receive a biological sample, which testing system is further arranged with means for measuring within said sample the total amount of at least a first biological marker in the form of an intracellular enzyme, and comprising means for analyzing the measured value of said intracellular enzyme, and based on the results thereof being arranged to communicate the risk of developing organ failure or presence of organ failure to an operator of said testing system. The present invention also relates to a method for analyzing a risk of developing organ failure, or analyzing presence of organ failure.

Abstract: A method of identifying an antifungal agent which targets a DHODH protein (alias PyrE, dihydroorotate dehydrogenase, EC: 1.3.99.11) of a fungus comprising contacting a candidate substance with a fungal DHODH protein and determining whether the candidate substance binds or modulates the DHODH protein, wherein binding or modulation indicates that the candidate substance is an antifungal agent. Specific examples concern Aspergillus fumigatus and Candida albicans DHODH proteins. DHODH inhibitors with a Quinazolinone core are also disclosed.

Abstract: Compositions and methods for screening for a disease or a disorder associated with a deficiency in frataxin in a subject using biomarkers for diseases or disorders associated with a deficiency in frataxin are disclosed. The compositions and methods include determining the acetylation status of mito-chondrial proteins. Also disclosed are methods of detecting progression of a disease or a disorder associated with a deficiency in frataxin in a subject and methods of monitoring effectiveness of a therapy for diseases or disorders associated with a deficiency in frataxin.

Abstract: A method of determining hypoxia in fetal scalp blood sampled during labor including the determination of total lactate dehydrogenase (LDH) in plasma obtained from the sample. The method can include the additional determination of K, Mg, Ca, AST, ALT, lactate in the plasma and/or blood. Increased values of one or more of LDH, Mg, Ca, AST, ALT, lactate are indicative of hypoxia in the fetus. Also disclosed is the use of a plasma separation apparatus in the method.

Abstract: Methods for diagnosing and treating cancer associated with an oncogenic Kras mutation in a subject are provided.

Abstract: The disclosure relates to methods of detecting a neural injury biomarker in a biological sample. The method includes subjecting a biological sample to an assay disclosed that produces a measurable signal and detecting the measurable signal. The presence or absence of the measurable signal indicates the presence or absence of the neural injury biomarker in the sample, and thereby diagnosing a subject as having a neural injury. The disclosure further relates to methods of determining the state of a subject's neural injury. Further disclosed are systems and devices useful in carrying out the methods disclosed.

Abstract: Using the methods of the present invention, intermediate (int) levels of aldehyde dehydrogenase (ALDH) activity reliably distinguished leukemic CD34+CD38? cells capable of engrafting immunodeficient mice, from residual normal hematopoietic stem cells that exhibited relatively higher ALDH activity. Minimal residual disease (MRD) detected during complete remission was enriched for the CD34+CD38?ALDHint leukemic cells, and the presence of these cells after therapy highly correlated with subsequent clinical relapse. The methods of the present invention can distinguish normal from leukemic CD34+CD38? cells, and identifies those AML cells associated with relapse. Methods of prediction of relapse of AML patients and methods of treatment are also provided.

Abstract: The present invention relates to a stabilizing composition useful for improving the stability of reagent for redox reaction, and a reagent composition for redox reaction having an improved stability. The reagent composition for redox reaction can be applied for a reagent for electrochemical biosensor.

Abstract: The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.

Abstract: Disclosed is a modified glucose dehydrogenases that has dramatically increased productivity in Escherichia coli and dramatically increased thermal stability, which is obtained by introducing specific amino acid mutations to glucose dehydrogenase derived from Botryotinia fuckeliana. Also disclosed is a modified glucose dehydrogenases that has dramatically increased productivity in E. coli and dramatically increased thermal stability, which is obtained by replacing two amino acid residues in glucose dehydrogenase of fungal origin with cysteine residues. The novel glucose dehydrogenase has a low reactivity to xylose.

Abstract: Provided is a dry reagent that allows measuring with good precision, in accordance with a transmission method that utilizes light of the ultraviolet region, increases or decreases of a nicotinamide coenzyme, in order to quantify a component contained in a liquid sample. A dry reagent 4 for performing a quantitative analysis of a specific component in a liquid sample S contains a nicotinamide coenzyme and a leveling agent for smoothing the dry reagent 4. Increases or decreases of the nicotinamide coenzyme are measured in accordance with a transmission method that utilizes light of the ultraviolet region. The leveling agent is a combination of an alkali and at least one type selected from among a saccharide and a surfactant.

Abstract: An analytical device for analysis of chemical or biological samples, a method of using such a device, based on rotation of the device, integrated sample dosing and optical detection, and a system comprising such a device are disclosed. The analytical device comprises a device body having a liquid processing unit. The liquid processing unit comprises a mixing chamber for mixing a sample with a reagent, a sample dosing chamber for delivering a defined volume of the sample to the mixing chamber, and a reagent channel for delivering the reagent to be mixed with the sample, wherein the mixing chamber also serves as a detection chamber.

Abstract: A three dimensional cell culture and bioreactor system is provided. The system comprises one or more cell culture chamber. Each cell culture chamber comprises an inlet port and an outlet port in fluid communication with the cell culture chamber. The cell culture chambers may be segregated or in fluid communication with one another. The systems may be used to conduct drug efficacy test, isolate certain cell types from a complex tissue sample of multiple cell types, allow for the ex vivo culturing of patient tissue samples to help guide the course of treatment, and conduct co-culture experiments.

Abstract: The invention relates to a method for determining biochemical parameters of a body fluid, wherein a sample of said body fluid in the form of a droplet is transported through a channel of a microfluidic system using a carrier liquid, mixed with a reagent thus initiating a chemical reaction between the sample and the reagent, and the result of the chemical reaction is measured, preferably with a spectrophotometer, whereby the said biochemical parameters of the body fluid are determined, characterised in that the material used for fabrication of the microfluidic system and the said carrier liquid is pair of Teflon and Fluorinert HFE-7100.

Abstract: An apparatus is provided for sensing an analyte in a fluid.

Abstract: The present invention relates to methods, compositions, and diagnostic tests for treating and diagnosing a proliferative disease that result in dysregulation of 6-phosphogluconate dehydrogenase. In particular, the methods and compositions include treatment of gefitinib/erlotinib resistant proliferative diseases such as lung cancer using a 6-phosphogluconate dehydrogenase antagonist.

Abstract: The purpose of the present invention is to provide an FAD-conjugated glucose dehydrogenase that is hard to be inhibited by the inhibitors such as 1,10-phenanthroline. The present invention relates to a modified glucose dehydrogenase (GLD), comprising an amino acid sequence of a wild-type FAD-conjugated glucose dehydrogenase (GLD) represented by SEQ ID NO: 1 having a substitution of at least one amino acid residue selected from the group consisting of amino acid residues at positions 298, 338, 340, 341, 343, 352, 354, 424, 426, 431 and 432, wherein the modified GLD has a reduced susceptibility to an inhibitor, as compared with the wild-type GLD, especially to said modified GLD, which has 40% or more of a relative activity when determined in a system wherein the inhibitor coexists at a final concentration of 1 mM based on an enzymatic activity when determined in a system wherein the inhibitor does not coexist.

Abstract: The present invention relates to a method for detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid in a sample, the method comprising the steps of: a) contacting a sample with a reagent mixture, wherein said reagent mixture comprises: (i) a solvent, (ii) a dye having an oxidized state and a reduced state, wherein the reduced state can be distinguished from the oxidized state and wherein the dye is initially present in the oxidized state, (iii) an electron transfer agent, (iv) a (D)-2-hydroxyglutarate dehydrogenase enzyme, and (v) a cofactor; and b) detecting (D)-2-hydroxyglutarate or (D)-2-hydroxyadipic acid by measuring the production of the reduced state of the dye. The invention further pertains to a method for diagnosing and/or monitoring a (D)-2-hydroxy-glutarate-associated disease in a subject. Encompassed by the invention is also a method for diagnosing a mutation in an isocitrate dehydrogenase (IDH) gene or in a (D)-2-hydroxyglutarate (D2HG) dehydrogenase enzyme gene in a subject.

Abstract: Systematic comparisons of samples of adjacent clinically non malignant and tumor tissue from cancer of the gingivo buccal complex obtained during surgical resection of the tumor revealed significant differences in protein expression between the cancer tissue and the adjacent clinically non malignant tissue in each patient. This study has identified a set of new proteins which can differentiate between the epithelial tissue from cancer patients which may be useful for high-through put early detection, prognosis, and potential targets for therapy.

Abstract: Human-derived fibroblast cells with copy number variation for alpha-synuclein, and methods of use thereof, are provided. For example, compositions and methods for high through-put screening of potential therapies for neurodegenerative disease such as Parkinson's disease are provided.

Abstract: The object of the present invention is to provide a method of determining 1,5-anhydroglucitol, including using (a) a protein which consists of the amino acid sequence of SEQ ID NO: 2; (b) a protein which consists of an amino acid sequence having deletion, substitution and/or addition of one or more amino acid residues in the amino acid sequence of SEQ ID NO: 2 and which has sorbose dehydrogenase activity; or (c) a protein which consists of an amino acid sequence having a homology of at least 60% with the amino acid sequence of SEQ ID NO: 2 and which has sorbose dehydrogenase activity.

Abstract: A method of determining hypoxia in fetal scalp blood sampled during labor comprises the determination of total lactate dehydrogenase (LDH) in plasma obtained from the sample. The method can comprise the additional determination of K, Mg, Ca, AST, ALT, lactate in the plasma and/or blood. Increased values of one or more of LDH, Mg, Ca, AST, ALT, lactate are indicative of hypoxia in the fetus. Also disclosed is the use of a plasma separation apparatus in the method.